HER-2 (Human epidermal growth factor receptor 2)

P=N/A, N=186, Not yet recruiting, Federico II University

P1, N=156, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P2, N=48, Active, not recruiting, Carey Anders, M.D. | Trial primary completion date: Apr 2026 --> Nov 2026 | Trial completion date: Jul 2026 --> Nov 2027

P1/2, N=40, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

P2, N=120, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

Conclusions In this retrospective, single-center study, 58.8% of patients with a positive SLN had additional axillary metastases following completion ALND, underscoring that residual nodal disease remains common and clinically significant. Conversely, 41.2% had no further axillary involvement, consistent with literature supporting selective de-escalation of axillary surgery in carefully selected patients.

Routine radiological staging investigation is advocated for invasive LRR. Majority of LRR were resectable, with nodal positivity rate comparable to the original cancer.

CTLA-4 expression was detected in 71% of CRCs. CTLA-4 positivity significantly decreased as tumor diameter decreased. There was no significant association between CTLA-4 expression and MSI or other prognostic parameters. Additionally, no significant correlation was found between CTLA-4 expression and median survival time. Nevertheless, the presence of CTLA-4 expression in the majority of CRCs is promising for anti-CTLA-4 therapy.

This integrative analysis characterized the ribociclib pharmacokinetic and exposure-QTcF relationship, revealed the population effect on both pharmacokinetic and QTcF response, and justified the 400-mg dose in EBC. This work illustrates the utility and impact of quantitative pharmacology in justifying different doses across different patient populations for oncology therapies.

Notably, EGFR depletion by an enhanced endobody suppressed lung cancer cell proliferation and tumor growth in vivo. Collectively, endobody is an innovative class of MPDs, offering promising therapeutic potential.

AI-assisted HER2 IHC scoring significantly improves interobserver consistency and provides quantitative support that helps address key limitations of conventional categorical HER2 assessment.

She completed adjuvant chemotherapy, radiotherapy, and HER2-targeted therapy, with no recurrence at 2-y follow-up. This case emphasizes deliberate review of the complete hybrid SPECT/CT field of view during parathyroid imaging.